Neurocrine shares skyrocket on promising PhII endometriosis data

Shares of Neurocrine Biosciences soared more than 50 percent in after-markets trading after the San Diego-based developer spelled out the success of a mid-stage trial of elagolix in a population of patients suffering from endometriosis. The gynecological drug hit its co-primary as well as secondary endpoints. Close to two thirds of the patients taking the drug responded to the treatment, with significant reductions in signs of dysmenorrhea, pelvic pain during menstruation, and non-menstrual...